These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 22254170)

  • 1. Optical imaging of metabolism in HER2 overexpressing breast cancer cells.
    Walsh A; Cook RS; Rexer B; Arteaga CL; Skala MC
    Biomed Opt Express; 2012 Jan; 3(1):75-85. PubMed ID: 22254170
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optical redox ratio differentiates breast cancer cell lines based on estrogen receptor status.
    Ostrander JH; McMahon CM; Lem S; Millon SR; Brown JQ; Seewaldt VL; Ramanujam N
    Cancer Res; 2010 Jun; 70(11):4759-66. PubMed ID: 20460512
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potential Biomarker for Triple-Negative Breast Cancer Invasiveness by Optical Redox Imaging.
    Feng M; Xu HN; Jiang J; Li LZ
    Adv Exp Med Biol; 2021; 1269():247-251. PubMed ID: 33966225
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Upregulation of mucin4 in ER-positive/HER2-overexpressing breast cancer xenografts with acquired resistance to endocrine and HER2-targeted therapies.
    Chen AC; Migliaccio I; Rimawi M; Lopez-Tarruella S; Creighton CJ; Massarweh S; Huang C; Wang YC; Batra SK; Gutierrez MC; Osborne CK; Schiff R
    Breast Cancer Res Treat; 2012 Jul; 134(2):583-93. PubMed ID: 22644656
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dual-labeled trastuzumab-based imaging agent for the detection of human epidermal growth factor receptor 2 overexpression in breast cancer.
    Sampath L; Kwon S; Ke S; Wang W; Schiff R; Mawad ME; Sevick-Muraca EM
    J Nucl Med; 2007 Sep; 48(9):1501-10. PubMed ID: 17785729
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dual inhibition of IGF1R and ER enhances response to trastuzumab in HER2 positive breast cancer cells.
    McDermott MSJ; Canonici A; Ivers L; Browne BC; Madden SF; O'Brien NA; Crown J; O'Donovan N
    Int J Oncol; 2017 Jun; 50(6):2221-2228. PubMed ID: 28498399
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modulating therapeutic effects of the c-Src inhibitor via oestrogen receptor and human epidermal growth factor receptor 2 in breast cancer cell lines.
    Fan P; McDaniel RE; Kim HR; Clagett D; Haddad B; Jordan VC
    Eur J Cancer; 2012 Dec; 48(18):3488-98. PubMed ID: 22658320
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HER2-Targeted PET Imaging and Therapy of Hyaluronan-Masked HER2-Overexpressing Breast Cancer.
    Pereira PMR; Ragupathi A; Shmuel S; Mandleywala K; Viola NT; Lewis JS
    Mol Pharm; 2020 Jan; 17(1):327-337. PubMed ID: 31804840
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nanobody-targeted photodynamic therapy induces significant tumor regression of trastuzumab-resistant HER2-positive breast cancer, after a single treatment session.
    Deken MM; Kijanka MM; Beltrán Hernández I; Slooter MD; de Bruijn HS; van Diest PJ; van Bergen En Henegouwen PMP; Lowik CWGM; Robinson DJ; Vahrmeijer AL; Oliveira S
    J Control Release; 2020 Jul; 323():269-281. PubMed ID: 32330574
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trastuzumab plus tamoxifen: anti-proliferative and molecular interactions in breast carcinoma.
    Ropero S; Menéndez JA; Vázquez-Martín A; Montero S; Cortés-Funes H; Colomer R
    Breast Cancer Res Treat; 2004 Jul; 86(2):125-37. PubMed ID: 15319565
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness and normal tissue toxicity of Auger electron (AE) radioimmunotherapy (RIT) with [
    Chan C; Fonge H; Lam K; Reilly RM
    Nucl Med Biol; 2020; 80-81():37-44. PubMed ID: 31706737
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human breast cancer tumor models: molecular imaging of drug susceptibility and dosing during HER2/neu-targeted therapy.
    Gee MS; Upadhyay R; Bergquist H; Alencar H; Reynolds F; Maricevich M; Weissleder R; Josephson L; Mahmood U
    Radiology; 2008 Sep; 248(3):925-35. PubMed ID: 18647846
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optical Redox Imaging Differentiates Triple-Negative Breast Cancer Subtypes.
    Jiang J; Feng M; Jacob A; Li LZ; Xu HN
    Adv Exp Med Biol; 2021; 1269():253-258. PubMed ID: 33966226
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Release of HER2 repression of trefoil factor 3 (TFF3) expression mediates trastuzumab resistance in HER2+/ER+ mammary carcinoma.
    Chong QY; You ML; Pandey V; Banerjee A; Chen YJ; Poh HM; Zhang M; Ma L; Zhu T; Basappa S; Liu L; Lobie PE
    Oncotarget; 2017 Sep; 8(43):74188-74208. PubMed ID: 29088778
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacological blockade of fatty acid synthase (FASN) reverses acquired autoresistance to trastuzumab (Herceptin by transcriptionally inhibiting 'HER2 super-expression' occurring in high-dose trastuzumab-conditioned SKBR3/Tzb100 breast cancer cells.
    Vazquez-Martin A; Colomer R; Brunet J; Menendez JA
    Int J Oncol; 2007 Oct; 31(4):769-76. PubMed ID: 17786307
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Poly (ADP-ribose) polymerase inhibition enhances trastuzumab antitumour activity in HER2 overexpressing breast cancer.
    García-Parra J; Dalmases A; Morancho B; Arpí O; Menendez S; Sabbaghi M; Zazo S; Chamizo C; Madoz J; Eroles P; Servitja S; Tusquets I; Yelamos J; Lluch A; Arribas J; Rojo F; Rovira A; Albanell J
    Eur J Cancer; 2014 Oct; 50(15):2725-34. PubMed ID: 25128455
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential response of triple-negative breast cancer to a docetaxel and carboplatin-based neoadjuvant treatment.
    Chang HR; Glaspy J; Allison MA; Kass FC; Elashoff R; Chung DU; Gornbein J
    Cancer; 2010 Sep; 116(18):4227-37. PubMed ID: 20549829
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PGC-1β regulates HER2-overexpressing breast cancer cells proliferation by metabolic and redox pathways.
    Victorino VJ; Barroso WA; Assunção AK; Cury V; Jeremias IC; Petroni R; Chausse B; Ariga SK; Herrera AC; Panis C; Lima TM; Souza HP
    Tumour Biol; 2016 May; 37(5):6035-44. PubMed ID: 26602383
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of Estrogen Receptor and Human Epidermal Growth Factor Receptor-2 Levels on the Efficacy of Trastuzumab: A Secondary Analysis of the HERA Trial.
    Loi S; Dafni U; Karlis D; Polydoropoulou V; Young BM; Willis S; Long B; de Azambuja E; Sotiriou C; Viale G; Rüschoff J; Piccart MJ; Dowsett M; Michiels S; Leyland-Jones B
    JAMA Oncol; 2016 Aug; 2(8):1040-7. PubMed ID: 27100299
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preclinical Activity of Abemaciclib Alone or in Combination with Antimitotic and Targeted Therapies in Breast Cancer.
    O'Brien N; Conklin D; Beckmann R; Luo T; Chau K; Thomas J; Mc Nulty A; Marchal C; Kalous O; von Euw E; Hurvitz S; Mockbee C; Slamon DJ
    Mol Cancer Ther; 2018 May; 17(5):897-907. PubMed ID: 29483214
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.